This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
The Zacks Analyst Blog Highlights: AZN, UNP, MO, SAP and UBER
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AZN, UNP, MO, SAP and UBER
Stock Market News for Jul 29, 2020
by Zacks Equity Research
Benchmarks slipped into the negative territory on Tuesday as investors kept a close watch on a second coronavirus relief package in consideration by lawmakers, along with mixed second-quarter corporate earnings report.
Top Stock Reports for AstraZeneca, Union Pacific & Altria
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca (AZN), Union Pacific (UNP) and Altria Group (MO).
Altria's (MO) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Altria's (MO) second-quarter 2020 results reflect adjusted OCI growth in oral tobacco and smokeable product segments. However, smokeable product revenues decline.
Altria (MO) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of 2.83% and -0.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's How Altria (MO) is Placed Just Ahead of Q2 Earnings
by Zacks Equity Research
Altria Group's (MO) second-quarter 2020 results are likely to reflect pricing gains. However, cigarette volumes have been affected by regulatory hurdles and rising health consciousness.
Earnings Preview: Altria (MO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Altria (MO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $40.87, marking a -1.61% move from the previous day.
Can Altria (MO) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Altria (MO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Altria (MO) Stock Moves -0.15%: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $40.21 in the latest trading session, marking a -0.15% move from the prior day.
Philip Morris' (PM) IQOS Gets FDA Nod to be Marketed as MRTP
by Zacks Equity Research
Philip Morris (PM) is likely to benefit from the FDA's latest move. Notably, the FDA authorizes IQOS's marketing as a modified risk tobacco product.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Riding high on its robust Medicare business line and strategic initiatives, Humana (HUM) holds potential to reap benefits for investors.
Phillip Morris Troubled by COVID-Related Woes & Pricing Aids
by Zacks Equity Research
Philip Morris (PM) anticipates coronavirus woes to have detrimental impacts on its second-quarter performance. Nonetheless, the company's pricing strength bodes well.
3 Investing Facts About Required Minimum Distributions You Need to Know - June 25, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
Altria (MO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $40.69, marking a -1.88% move from the previous day.
Altria Focuses on Pricing & RRPs Amid Soft Cigarette Volumes
by Zacks Equity Research
Altria's (MO) focus on oral tobacco products along with solid pricing bodes well, though cigarette volumes have been soft due to rising health consciousness and government regulations.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $39.13 in the latest trading session, marking a -0.41% move from the prior day.
Retirees Should Know These 3 Facts About Required Minimum Distributions - June 10, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
BTI or MO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BTI vs. MO: Which Stock Is the Better Value Option?
Top Analyst Reports for Apple, Verizon & PayPal
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Verizon Communications (VZ) and PayPal (PYPL).
Altria (MO) Down 0.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Altria (MO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tobacco Industry Outlook Smoking Hot on Pricing & RRP Focus
by Vrishali Bagree
Companies in the tobacco industry are likely to benefit from their efficient pricing strategy and focus on low-risk products amid receding cigarette volumes.
Retirees Should Know These 3 Facts About Required Minimum Distributions - May 14, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
The Zacks Analyst Blog Highlights: Amgen, BHP, Altria, Apple and Target
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, BHP, Altria, Apple and Target
Top Research Reports for Amgen, BHP, Altria & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), BHP Group (BHP) and Altria Group (MO).